In the E2100 Breast cancer trial, VEGF polymorphisms (VEGF-2578 AA and VEGF-1154 AA) genotypes were associated with a superior median OS in the Bevacizumab arm compared with other genotypes (37 months and 46 months respectively compared to 25 months in the control arm) [47]. Here, VEGFA is linked to breast cancer.